Junevity to Present Breakthrough Research on siRNA Therapeutics at American Aging Association’s 2026 Annual Meeting
The company’s co-founder will deliver an oral presentation with the first ever data showing an siRNA therapeutic can restore global gene networks back to health in vivo
The company to present applications of its RESET Platform for siRNA therapeutic development in neurodegeneration and Parkinson’s Disease
Junevity, a biotechnology company on a mission to extend lifespan and healthspan with siRNA (silencing RNA) therapeutics, today announced co-founder and chief scientific officer Dr. Janine Sengstack will be presenting the first ever data demonstrating that siRNA therapeutics can restore global gene networks to a healthier state. The data will be featured during an oral presentation at the American Aging Association’s Annual Meeting on at 3:45 p.m. MDT on Weds, June 3rd in Provo, Utah.
In January 2026, Dr. Sengstack published foundational research in Proceedings of the National Academy of Sciences (PNAS) validating that precise modulation of individual transcription factors can reverse core hallmarks of cellular aging and restore tissue function in vivo. This research was the first to show that repressing a single transcription factor can rejuvenate global gene expression in vitro. Single-target repression enables siRNA as a modality, significantly improving therapeutic translatability with once every 6-12 month dosing, low manufacturing costs and a validated human safety profile.
